Last reviewed · How we verify

Sprains and Strains — Treatment Landscape & Competitive Intelligence

Sprains and Strains (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sprains and Strains, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Qutenza CAPSAICIN Averitas capsaicin Transient receptor potential cation channel subfamily V member 1 2009-01-01
Salonpas METHYL SALICYLATE Hisamitsu Pharm Co methyl salicylate 2008-01-01
Voltaren DICLOFENAC Hisamitsu Pharmaceutical Co., Inc Nonsteroidal Anti-inflammatory Drug Prostaglandin G/H synthase 2 1988-01-01
Arthrotec Diclofenac Sodium Pfizer diclofenac Acid-sensing ion channel 3 1988-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Sprains and Strains
  2. Averitas · 1 drug in Sprains and Strains
  3. Hisamitsu Pharm Co · 1 drug in Sprains and Strains
  4. Hisamitsu Pharmaceutical Co., Inc · 1 drug in Sprains and Strains
  5. Pfizer · 1 drug in Sprains and Strains

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sprains and Strains:

Cite this brief

Drug Landscape (2026). Sprains and Strains — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sprains-and-strains. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing